Diabetic Retinopathy Pipeline Analysis Report 2026

Report Coverage

The Diabetic Retinopathy Pipeline Analysis Report by Expert Market Research gives comprehensive insights into diabetic retinopathy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for diabetic retinopathy. The diabetic retinopathy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The diabetic retinopathy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with diabetic retinopathy treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to diabetic retinopathy.

Read more about this report - Request a Free Sample

Diabetic Retinopathy Pipeline Outlook

Diabetic retinopathy is a diabetes-related eye condition caused by damage to retinal blood vessels, leading to fluid leakage, swelling, and impaired vision. Over time, blocked or abnormal vessel growth can result in severe vision loss or blindness. It affects approximately 103 million people globally, with nearly five million cases resulting in blindness.

Diabetic retinopathy treatments include anti-vascular endothelial growth factor injections, laser therapy, and surgical interventions to reduce retinal swelling and prevent further vision loss. These therapies aim to stabilize or improve vision while controlling disease progression. In May 2025, the FDA approved Roche’s Susvimo for diabetic retinopathy, offering a novel Port Delivery Platform that allows continuous ranibizumab delivery. With a single treatment every nine months, Susvimo helps maintain vision and reduce disease progression, providing an alternative to frequent monthly injections and expanding options in the diabetic retinopathy drug pipeline.

Diabetic Retinopathy Epidemiology

The prevalence of diabetic retinopathy is increasing worldwide, highlighting the growing need for effective therapies. According to Mohammed Ramzi Mohammed et al., 2025, diabetic retinopathy affects approximately 30–40% of individuals with diabetes globally. As per Prevent Blindness, in 2021, an estimated 9.6 million people in the United States, representing 26.4% of those with diabetes, had diabetic retinopathy, while 1.84 million, or 5.1%, had vision-threatening diabetic retinopathy, with higher prevalence among Black 8.7% and Hispanic 7.1% populations. According to Expert Market Research, a study in 21 districts in India reported diabetic retinopathy prevalence at 16.9%, with sight-threatening diabetic retinopathy at 3.6%. As per Favas KT Muhammed et al., 2025, global cases are projected to increase from 103 million in 2020 to 161 million by 2045. These trends underscore the urgent need for advanced drug development in the diabetic retinopathy pipeline.

Diabetic Retinopathy – Pipeline Therapeutic Assessment

Diabetic Retinopathy Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II at 30%, covers a major share of the total diabetic retinopathy clinical trials. It is followed by phase III at 23%, phase I at 20%, early phase I at 14.5%, and phase IV at 11%. The significant representation across advanced phases underscores a strong clinical development landscape, driving innovation, expanding therapeutic options, and supporting sustained growth in the market.

Diabetic Retinopathy Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the diabetic retinopathy pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The diabetic retinopathy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for diabetic retinopathy. Oral small-molecule therapies are emerging as a promising approach in the diabetic retinopathy pipeline. For instance, APX3330, an oral tablet, is under evaluation for its ability to slow vision loss in early-stage patients. The drug works by targeting oxidative stress pathways in the retina, providing a non-invasive alternative to conventional anti-VEGF injections.

Diabetic Retinopathy Clinical Trials – Key Players

The EMR report for the diabetic retinopathy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed diabetic retinopathy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in diabetic retinopathy clinical trials:

• Boehringer Ingelheim
• Vantage Biosciences Ltd.
• Beletalent (Zhuhai) Pharmaceutical Co., Ltd.
• Invirsa, Inc.
• Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
• Therini Bio Pty Ltd.
• Perfuse Therapeutics, Inc.
• Kodiak Sciences Inc.
• Ocular Therapeutix, Inc.
• Genentech, Inc.
• AbbVie
• REGENXBIO Inc.

Diabetic Retinopathy – Emerging Drugs Profile

Key Questions Answered in the Diabetic Retinopathy Pipeline Insight Report

• Which companies/institutions are leading the diabetic retinopathy drug development?
• Which company is leading the diabetic retinopathy pipeline development activities?
• What is the current diabetic retinopathy commercial assessment?
• What are the opportunities and challenges present in the diabetic retinopathy pipeline landscape?
• What is the efficacy and safety profile of diabetic retinopathy pipeline drugs?
• Which company is conducting major trials for diabetic retinopathy drugs?
• Which companies/institutions are involved in diabetic retinopathy collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in diabetic retinopathy?

Reasons To Buy This Report

The Diabetic Retinopathy Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for diabetic retinopathy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into diabetic retinopathy collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Diabetic Retinopathy Treatment Market

Diabetic Retinopathy Epidemiology

Proliferative Diabetic Retinopathy Pipeline Analysis